COMPANY

PAVmed Inc.

Also known as PAVmed · 5 sources

Profile checked Oct 10, 2026

Keywords: Chronic Kidney Disease stage3 Chronic Kidney Disease stage4 Poor Vascular Access Carpal Tunnel Syndrome PAVmed PortIO™ Intraosseous Infusion System

2Trials (company is sponsor)2NIH grants

Funding and NIH signals

SEC Form D raise Raised $30M (Form D filed Feb 17, 2026). SEC Form D 0001094891-26-000056 (Feb 17, 2026)
Evidence (1 event)
- Feb 17, 2026 · SEC Form D 0001094891-26-000056
  Name of Issuer: PAVmed Inc.; CIK: 1624326; Address: New York, NY; Submission type: D; Filing date: 2026-02-17; Industry Group: Other Health Care; Date of First Sale: 2026-02-03; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 60000000; Total Amount Sold: 30000000; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Feb 4, 2026 Debt Debt: $30M (not counted as a raise), announced Feb 4, 2026. Source: SEC filing. source ↗
Jan 20, 2022 Trial start Not phased (device or behavioral study): PR-0164 First in Human Clinical Trial of the PAVmed PortIO Intraosseous Infusion System source ↗
Jan 5, 2019 Trial start Not phased (device or behavioral study): PAVmed CarpX Device Clinical Study source ↗

Funding

Debt: $30.0M. Last 2 years.

Feb 4, 2026 Debt: $30M (not counted as a raise), announced Feb 4, 2026. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT06037265	PR-0164 First in Human Clinical Trial of the PAVmed PortIO Intraosseous Infusion System	Not phased (device or behavioral study)	Completed	Jan 20, 2022	Jul 29, 2024 (actual)
NCT03747510	PAVmed CarpX Device Clinical Study	Not phased (device or behavioral study)	Completed	Jan 5, 2019	Dec 30, 2019 (actual)

NIH awards 2

Annual award amounts. Total $1.8M.

Aug 4, 2025 NIH award 5R44MD019611-02 FY2025: $931,489 awarded for that fiscal year; activity R44 (SBIR); PI DEGUZMAN, BRIAN; recipient as written: PAVMED INC., NEW YORK, NY. Bridging the Gap: Enhancing Cancer Care for Underserv source ↗
Sep 22, 2024 NIH award 1R44MD019611-01 FY2024: $892,112 awarded for that fiscal year; activity R44 (SBIR); PI DEGUZMAN, BRIAN; recipient as written: PAVMED INC., NEW YORK, NY. Bridging the Gap: Enhancing Cancer Care for Underserv source ↗